Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) shares rose 1.8% during trading on Friday . The stock traded as high as $22.08 and last traded at $21.74, with a volume of 164,682 shares traded. The stock had previously closed at $21.35.

SUPN has been the topic of several recent analyst reports. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Piper Jaffray Cos. lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 price objective on the stock. in a report on Monday, July 18th. Jefferies Group reissued a “buy” rating and set a $28.00 price objective (up previously from $23.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 4th. Finally, Northland Securities lowered Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price objective on the stock. in a report on Monday, July 18th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $24.50.

The firm has a 50 day moving average of $22.04 and a 200 day moving average of $17.97. The stock has a market cap of $1.09 billion and a P/E ratio of 45.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.05. During the same period in the prior year, the company earned $0.03 earnings per share. The firm had revenue of $50.40 million for the quarter, compared to analyst estimates of $49.67 million. The firm’s quarterly revenue was up 43.6% on a year-over-year basis. On average, equities research analysts expect that Supernus Pharmaceuticals Inc. will post $0.68 earnings per share for the current fiscal year.

In related news, CFO Gregory S. Patrick sold 3,395 shares of the stock in a transaction that occurred on Thursday, July 14th. The stock was sold at an average price of $22.00, for a total transaction of $74,690.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

An institutional investor recently raised its position in Supernus Pharmaceuticals stock. New York State Common Retirement Fund increased its stake in shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) by 3.7% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 205,981 shares of the specialty pharmaceutical company’s stock after buying an additional 7,299 shares during the period. New York State Common Retirement Fund owned approximately 0.42% of Supernus Pharmaceuticals worth $2,768,000 at the end of the most recent reporting period.

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.